Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
暂无分享,去创建一个
Marina V Backer | Joseph M Backer | Vimalkumar A. Patel | F. Blankenberg | K. Claffey | M. Backer | J. Backer | Francis G Blankenberg | Zoya Levashova | Vimalkumar Patel | Brian T Jehning | Kevin Claffey | Z. Levashova
[1] J. Mestan,et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.
[2] S. Gambhir,et al. microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .
[3] L. Ellis,et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. , 2003, Trends in molecular medicine.
[4] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[5] William R. Wagner,et al. Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor , 2003, Circulation.
[6] Stefanie Mandl,et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] J. Isner,et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. , 1997, The American journal of pathology.
[8] Vimalkumar A. Patel,et al. In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[9] K. Claffey,et al. Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. , 2006, Biomaterials.
[10] K. Claffey,et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature , 2005, Molecular Cancer Therapeutics.
[11] J. Tonn,et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. , 2002, The Journal of clinical investigation.
[12] Wei Zhang,et al. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model , 2004, Angiogenesis.
[13] H. Saji,et al. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. , 1999, Bioconjugate chemistry.
[14] P. Angelberger,et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Huang,et al. RESPONSE: re: initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models , 2000, Journal of the National Cancer Institute.
[16] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[17] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[18] M. Dewhirst,et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.
[19] T. Saga,et al. Control of radioactivity pharmacokinetics of 99mTc-HYNIC-labeled polypeptides derivatized with ternary ligand complexes. , 2002, Bioconjugate chemistry.
[20] M. Bryckaert,et al. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects , 1991, Journal of cellular physiology.
[21] A. Harris,et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.
[22] P. Valent,et al. Characterization of 123I‐vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy , 2001, International journal of cancer.
[23] James H Thrall,et al. Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.
[24] A. Guha,et al. A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] M. Luisa Iruela-Arispe,et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.
[26] Gloria H Heppner,et al. Nontransgenic models of breast cancer , 2000, Breast Cancer Research.
[27] G. Vrensen,et al. Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[28] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[29] W. Schima,et al. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[30] M. Backer,et al. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. , 2001, Bioconjugate chemistry.
[31] M. Backer,et al. Functionally active VEGF fusion proteins. , 2001, Protein expression and purification.
[32] R. Haubner,et al. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.